HEPA HEPION PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, HEPION PHARMACEUTICALS INC reported revenue of n/a, net income of −$1.25M and diluted EPS of −$0.08; for the fiscal year ended December 2025 revenue was n/a.
HEPA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$4.16M, net income −$8.28M (margin n/a), EPS −$0.88
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$19.3M, net income −$13.2M (margin n/a), EPS −$107.35
- Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$48.4M, net income −$48.9M (margin n/a), EPS −$616.07
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$45.5M, net income −$42.2M (margin n/a), EPS −$11.90
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$30.4M, net income −$32.7M (margin n/a), EPS −$0.47
HEPA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$1.25M, EPS −$0.08
- Quarter ended Mar 31, 2026: revenue n/a, net income −$811K, EPS −$0.07
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$657K, EPS $1.40
- Quarter ended Sep 30, 2025: revenue n/a, net income −$473K, EPS −$0.04
- Quarter ended Jun 30, 2025: revenue n/a, net income −$1.04M, EPS −$0.09
- Quarter ended Mar 31, 2025: revenue n/a, net income −$6.11M, EPS −$2.15
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$1.55M, EPS −$9.01
- Quarter ended Sep 30, 2024: revenue n/a, net income −$4.87M, EPS −$36.21
- Quarter ended Jun 30, 2024: revenue n/a, net income −$3.93M, EPS −$34.00
- Quarter ended Mar 31, 2024: revenue $0, net income −$2.85M, EPS −$28.13
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$11.1M, EPS −$606.17
- Quarter ended Sep 30, 2023: revenue $0, net income −$10.5M, EPS −$2.74
- Quarter ended Jun 30, 2023: revenue $0, net income −$14.1M, EPS −$3.68
- Quarter ended Mar 31, 2023: revenue $0, net income −$13.3M, EPS −$3.48
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$6.81M, EPS −$2.62
- Quarter ended Sep 30, 2022: revenue $0, net income −$8.55M, EPS −$2.24
- Quarter ended Jun 30, 2022: revenue $0, net income −$19.9M, EPS −$5.22
- Quarter ended Mar 31, 2022: revenue $0, net income −$6.93M, EPS −$1.82
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$9.72M, EPS −$0.13
- Quarter ended Sep 30, 2021: revenue $0, net income −$9.27M, EPS −$0.12
HEPA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$3.27M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$18.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$40.9M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$35.0M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$31.2M, share buybacks n/a
HEPA balance sheet
- Jun 30, 2026: cash n/a, total assets $1.93M, total liabilities $649K, shareholders' equity $1.28M
- Mar 31, 2026: cash n/a, total assets $2.71M, total liabilities $849K, shareholders' equity $1.86M
- Dec 31, 2025: cash n/a, total assets $3.07M, total liabilities $402K, shareholders' equity $2.67M
- Sep 30, 2025: cash n/a, total assets $3.74M, total liabilities $416K, shareholders' equity $3.32M
- Jun 30, 2025: cash n/a, total assets $4.51M, total liabilities $709K, shareholders' equity $3.80M
- Mar 31, 2025: cash n/a, total assets $6.32M, total liabilities $2.42M, shareholders' equity $3.90M
- Dec 31, 2024: cash n/a, total assets $1.61M, total liabilities $3.48M, shareholders' equity −$1.86M
- Sep 30, 2024: cash n/a, total assets $3.72M, total liabilities $4.12M, shareholders' equity $407K
Is HEPA profitable?
No. HEPION PHARMACEUTICALS INC lost $3.19M over the last four quarters.
What is HEPA's EPS?
Diluted earnings per share over the last four quarters were $1.21; −$0.08 in the latest quarter.